Scinovex
article Open AccessTop 1% cited

Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship

Clinical Infectious Diseases · 2006 · Vol. 44(2) · pp. 159–177
Timothy H. DellitRobert C. OwensJohn E. McGowanDale N. GerdingRobert A. WeinsteinJohn P. BurkeW. Charles HuskinsDavid L. PatersonNeil O. FishmanChristopher CarpenterPatrick J. BrennanMarianne BilleterThomas M. Hooton

Abstract

This document presents guidelines for developing institutional programs to enhance antimicrobial stewardship, an activity that includes appropriate selection, dosing, route, and duration of antimicrobial therapy. The multifaceted nature of antimicrobial stewardship has led to collaborative review and support of these recommendations by the following organizations: American Academy of Pediatrics, American Society of Health-System Pharmacists, Infectious Diseases Society for Obstetrics and Gynecology, Pediatric Infectious Diseases Society, Society for Hospital Medicine, and Society of Infectious Diseases Pharmacists. The primary goal of antimicrobial stewardship is to optimize clinical outcomes while minimizing unintended consequences of antimicrobial use, including toxicity, the selection of pathogenic organisms (such as Clostridium difficile), and the emergence of resistance. Thus, the appropriate use of antimicrobials is an essential part of patient safety

Antibiotic Use and ResistanceBacterial Identification and Susceptibility TestingAntimicrobial Resistance in StaphylococcusAntimicrobial stewardshipMedicineEpidemiologyHealth careStewardship (theology)Economic growthIntensive care medicineEnvironmental healthPolitical scienceAntibiotic resistance

MeSH terms

Anti-Bacterial AgentsDecision Support TechniquesDrug Administration RoutesDrug UtilizationFormularies, Hospital as TopicHospitalsPharmacy Service, HospitalSocieties, MedicalSoftwareUnited StatesPractice Guidelines as Topic

Funding

  • Pfizer
  • AstraZeneca
  • Viropharma
  • Gojo Industries
Citations
3,343
FWCI
71.86
field-weighted impact
References
198
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.